Harnessing the power of Artificial Intelligence to unlock further potential of known drugs for orphan diseases

We leverage the power of Artificial Intelligence to repurpose drugs for orphan diseases

We are a team of talented scientists with a passion for innovation

STANDARD DRUG DISCOVERY AND DEVELOPMENT

$1 to $2 billion
cost of developing a new drug
10 to 15 years
to develop a new drug
90%
of new chemical entities fail before they even reach the clinics

WE CAN REDUCE THOSE NUMBERS TO

$250k to $50M
cost of developing a new drug
4 to 5 years
to develop a new drug

OUR APPROACH

Leveraging the power of Artificial Intelligence

Focused on orphan diseases

Repurposing drugs for new therapeutic indications

Learn about our Unique Approach

PROPRIETARY PIPELINE

7 000

Only 5% have approved treatments

The main focus of our pipeline are Orphan diseases with a high unmet medical need

Learn about our pipeline

PARTNERSHIP

Workflow adapted to your needs

Learn how you can work with us

Our business model is a combination of in-house development and external collaborations. We have entered into multiple industry partnerships, as well as academic collaborations

OUR PERFORMANCE INDICATORS

77%
of our starting programs revealed positive hits that were confirmed at the laboratory bench and that were patentable
27%
of those hits are in preclinical or clincial development
20%
of those preclinical or clinical programs have clinical stage Phase 2 positive results

WE COOPERATE WITH

SOM BIOTECH IN THE MEDIA

LATEST NEWS

SOM Biotech announces the presentation of the Phase2b study results in Huntington Chorea Patients at the HDG Conference in Cincinnati

October 15, 2024

SOM Biotech announces the database lock of its Phase2b study with SOM3355 in Huntington’s chorea patients and looks for top-line results in August.

SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligent (AI) platform, is pleased to announce the database lock of the Phase 2b study SOMCT03 with SOM3355 for the treatment of chorea in Huntington’s Disease. Press Release

SOM Biotech lecture on drug repurposing in Rare Diseases

The Continuous Education Institute of the University of Barcelona (IL3) has invited Dr. Insa to lecture on drug repurposing in rare diseases. The event took place on July 10th in the summer university course titled “Rare diseases. From diagnostics to treatment” Course "Enfermedades raras. Del diagnóstico a la terapia" (ub.edu)

The Brazilian Journal of Implantology and Health Sciences cites SOM3355 as a promising therapy for chorea in Huntington’s disease.

The current issue of The Brazilian Journal of Implantology and Health Sciences (Volume 6, Issue 6 (2024), Page 1040-105) cites SOM3355 as a promising therapy for chorea in Huntington’s disease.

SOM Biotech appoints George G. Montgomery as Strategic Corporate Advisor

SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligent platform, has appointed George G. Montgomery as Strategic Corporate Advisor to the Board.

SOM Biotech announces the completion of recruitment in the Phase IIb study of the treatment of chorea in Huntington’s disease patients with SOM3355

SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligence platform (SOMAIPRO®), is pleased to announce that the recruitment of the Phase IIb clinical study with SOM3355 as a treatment for Huntington’s chorea has been completed.